Preterax indications
Treatment of essential hypertension.
Preterax 5 mg/1.25 mg: Subjects whose blood pressure is not adequately controlled by Perindopril (Preterax) alone.
Preterax 10 mg/2.5 mg: Substitution therapy in patients already controlled with Perindopril (Preterax) and Indapamide (Preterax) given concurrently at the same dose level.
Preterax description
Each Preterax 2.5 mg tablet contains Perindopril (Preterax) argnine 2.5 mg, Indapamide (Preterax) 0.625 mg and excipients.
Each Preterax 5 mg tablet contains Perindopril (Preterax) arginine 5 mg and Indapamide (Preterax) 1.25 mg. It also contains the following excipients: Hydrophobic colloidal silica 0.25 mg, lactose monohydrate 61.55 mg, magnesium stearate 0.45 mg and microcrystalline cellulose 22.5 mg.
Each Preterax 10 mg tablet contains Perindopril (Preterax) arginine 10 mg and Indapamide (Preterax) 2.5 mg.
Preterax dosage
Preterax 5 mg/1.25 mg Tablet: If blood pressure is not controlled after 1 month of treatment, the dose should be titrated to one 5 mg/1.25 mg tablet/day as a single dose, preferably to be taken in the morning and before a meal. When clinically appropriate, direct change from monotherapy to 5 mg/1.25 mg film-coated tablet may be considered.
Preterax 10 mg/2.5 mg Tablet: One 10 mg/2.5 mg as a single dose, preferably to be taken in the morning and before a meal.
Elderly: In elderly, the plasma creatinine must be adjusted in relation to age, weight and gender. Elderly patients can be treated with Preterax 5 mg/1.25 mg and 10 mg/2.5 mg if renal function is normal and after considering blood pressure response.
Renal Impairment: In severe renal impairment (creatinine clearance <30 mL/min), treatment is contraindicated.
In moderate renal impairment (creatinine clearance <60 mL/min), treatment is contraindicated to Preterax 10 mg/2.5 mg.
Preterax 5 mg/1.25 mg Tablet: In patients with moderate renal impairment (creatinine clearance 30-60 mL/min), it is recommended to start treatment with the adequate dosage of the free combination.
In patients with creatinine clearance ≥60 mL/min, no dose modification is required.
Usual medical follow-up will include frequent monitoring of creatinine and potassium.
Hepatic Impairment: In severe hepatic impairment, treatment is contraindicated.
In patients with moderate hepatic impairment, no dose modification is required.
Preterax interactions
Avoid Preterax with lithium, potassium-sparing diuretics (eg, spironolactone, triamterene), potassium salts.
Caution in use of Preterax with the following drugs: Other medicines for treating high blood pressure; procainamide; allopurinol; terfenadine or astemizole; corticosteroids used to treat various conditions including severe asthma and rheumatoid arthritis; immunosuppressants used for the treatment of autoimmune disorders or following transplant surgery to prevent rejection (eg, cyclosporin); medicines for the treatment of cancer; erythromycin by injection; halofantrine; pentamidine; injectable gold; vincamine; bepridil; sulfopride; medicines used for heart rhythm problems (eg, quinidine, hydroquinidine, disopyramide, amiodarone, sotalol); digoxin or other cardiac glycosides; baclofen; medicines used to treat diabetes eg, insulin or metformin; calcium, including calcium supplements; stimulant laxatives (eg, senna); nonsteroidal anti-inflammatory drugs (eg, ibuprofen) or high-dose salicylates (eg, aspirin); amphotericin B by injection; medicines to treat mental disorders eg, depression, anxiety, schizophrenia (eg, tricyclic antidepressants, neuroleptics); tetracosactide.
Preterax side effects
The administration of Perindopril (Preterax) inhibits the renin-angiotensin-aldosterone axis and tends to reduce the potassium loss caused by Indapamide (Preterax). Two percent (2%) of the patients on treatment with Preterax 2.5 mg/0.625 mg, 4% of the patients on treatment with Preterax 5 mg/1.25 mg and 6% of the patients on treatment with Preterax 10 mg/2.5 mg experience hypokalaemia (potassium level <3.4 micromol/L).
The following undesirable effects could be observed during treatment and ranked under the following frequency: Very common (≥1/10); common (≥1/100, <1/10); uncommon (≥1/1000, <1/100); rare (≥1/10000, <1/1000), very rare (<1/10000), not known (cannot be estimated from the available data).
Blood and the Lymphatic System Disorders: Very Rare: Thrombocytopenia, leucopenia/neutropenia, agranulocytosis, aplastic anaemia, haemolytic anaemia. Anaemia has been reported with ACE inhibitors in specific circumstances (patients who have had kidney transplants, patients undergoing haemodialysis).
Psychiatric Disorders: Uncommon: Mood or sleep disturbances.
Nervous System Disorders: Common: Paraesthesia, headache, dizziness, vertigo. Very Rare: Confusion.
Eye Disorders: Common: Vision disturbance.
Ear and Labyrinth Disorders: Common: Tinnitus.
Vascular Disorders: Common: Hypotension whether orthostatic or not.
Cardiac Disorders: Very Rare: Arrhythmia including bradycardia, ventricular tachycardia, atrial fibrillation, angina pectoris and myocardial infarction possibly secondary to excessive hypotension in high-risk patients.
Respiratory, Thoracic and Mediastinal Disorders: Common: A dry cough has been reported with the use of ACE inhibitors. It is characterised by its persistence and by its disappearance when treatment is withdrawn. An iatrogenic aetiology should be considered in the presence of this symptom. Dypsnoea. Uncommon: Bronchospasm. Very Rare: Eosinophilic pneumonia, rhinitis.
Gastrointestinal Disorders: Common: Constipation, dry mouth, nausea, vomiting, abdominal pain, dysgeusia, dyspepsia, diarrhoea, epigastric pain, anorexia, abdominal pains, taste disturbance. Very Rare: Pancreatitis.
Hepato-Biliary Disorders: Very Rare: Hepatitis either cytolytic or cholestatic. Not known: In case of hepatic insufficiency, there is a possibility of onset of hepatic encephalopathy.
Skin and Subcutaneous Tissue Disorders: Common: Rash, pruritus, maculopapular eruptions. Uncommon: Angioedema of face, extremities, lips, mucous membranes, tongue, glottis and/or larynx, urticaria. Hypersensitivity reactions, mainly dermatological, in subjects with a predisposition to allergic and asthmatic reactions. Purpura, possible aggravation of preexisting acute disseminated lupus erythematosus. Very Rare: Erythema multiforme, toxic epidermic necrolysis, Stevens-Johnson syndrome. Cases of photosensitivity reactions have been reported.
Musculoskeletal, Connective Tissue and Bone Disorders: Common: Muscle cramps.
Renal and Urinary Disorders: Uncommon: Renal insufficiency. Very Rare: Acute renal failure.
Reproductive System and Breast Disorders: Uncommon: Impotence.
General Disorders and Administration Site Conditions: Common: Asthenia. Uncommon: Sweating.
Investigations: Potassium depletion with particularly serious reduction in levels of potassium in some at risk populations. Reduced sodium levels with hypovolaemia causing dehydration and orthostatic hypotension. Increase in uric acid levels and in blood glucose levels during treatment. Slight increase in urea and in plasma creatinine levels, reversible when treatment is stopped. This increase is more frequent in cases of renal artery stenosis, arterial hypertension treated with diuretics, renal insufficiency. Increased levels of potassium, usually transitory. Rare: Raised plasma calcium levels.
Preterax contraindications
Linked to Perindopril (Preterax): Preterax should never be used in cases of hypersensitivity to Perindopril (Preterax) or to any other angiotensin-converting enzyme inhibitors; previous history of angioneurotic oedema (Quincke's oedema) linked to treatment with an angiotensin-converting enzyme inhibitor; hyperkalemia; pregnancy; lactation.
Preterax 2.5 mg: Hereditary or idiopathic angioneurotic oedema.
Preterax 2.5 mg/5 mg is generally not recommended in combinations with potassium-sparing diuretics, potassium salts, lithium; bilateral renal artery stenosis or single functioning kidney; increased potassium levels.
Linked to Indapamide (Preterax): Preterax should never be used in cases of hypersensitivity to sulphonamides; severe renal failure (creatinine clearance <30 mL/min), hepatic encephalopathy, severe impairment of liver function; hypokalaemia.
As a general rule, use of Preterax is not recommended in combination with non-antiarrhythmic drugs producing Torsade de pointes.
Linked to Preterax 2.5 mg: Hypersensitivity to any of the excipients.
As there is a lack of available data, Preterax 2.5 mg must not be used in dialysis patients; patients with untreated decompensated cardiac insufficiency.
Active ingredient matches for Preterax:
Indapamide/Perindopril in Austria, Belgium, Costa Rica, Dominican Republic, El Salvador, France, Greece, Guatemala, Honduras, Ireland, Italy, Luxembourg, Malta, Mexico, Myanmar, Nicaragua, Panama, Peru, Philippines, Portugal, Singapore, South Africa, Spain, Taiwan, Turkey, Vietnam.
Indapamide/Perindopril arginine in Myanmar.
Indapamide/Perindopril erbumine in France.
| Unit description / dosage (Manufacturer) | Price, USD |
| Tablet; Oral; Indapamide 0.625 mg; Perindopril Erbumine 2 mg | |
| Preterax 30's | $ 32.22 |
| Preterax 28's | |
| Preterax tab 30's (Servier) | $ 36.18 |
| Preterax tab 10 mg/2.5 mg 30's (Servier) | |
| Preterax tab 5 mg/1.25 mg 30's (Servier) | |
| Preterax tab 2.5 mg/0.625 mg 30's (Servier) | |
List of Preterax substitutes (brand and generic names): | |
| Prestarium Plus (Poland) | |
| Pretanix Komb 4 mg/1.25 mg (Hungary) | |
| Pretanix Komb Forte (Hungary) | |
| Pretanix Komb Forte 8 mg/2.5 mg (Hungary) | |
| Pretanix Komb. (Hungary) | |
| Preterax 10 (Argentina) | |
| Preterax 5 (Argentina) | |
| Preterax Argenine (Malta, Oman) | |
| Preterax Forte | |
| Tablet; Oral; Indapamide 1.25 mg; Perindopril Erbumine 4 mg | |
| PRETERAX N (Germany) | |
| PRETERAX N 2,5mg/0,625mg (Germany) | |
| Preterax-2.5/0.625 (Luxembourg) | |
| Preterax-5/1.25 (Luxembourg) | |
| Preterax-Arginin (Austria) | |
| Preterax-Arginin 2,5 mg/0,625 mg (Austria) | |
| Preterian (Netherlands) | |
| Prexanil Combi (Serbia, Slovenia) | |
| Prexanil Combi HD (Serbia) | |
| Prexanil Combi LD (Serbia) | |
| Prexum Combi (Australia) | |
| Prexum Plus (South Africa) | |
| Pricoron Combi (Czech Republic, Romania) | |
| Pricoron Duo (Lithuania) | |
| Prilamid (Georgia) | |
| Prindex Combi (Slovakia) | |
| Prindex Plus (Estonia) | |
| Repres Plus (Bangladesh) | |
| Romapal (Lithuania, Poland) | |
| Serperil Plus (Turkey) | |
| Spec Perindopril Plus (South Africa) | |
| Teraxans (Bulgaria, Italy, Lithuania, Slovenia) | |
| Terry White Chemists Perindopril/Indapamide (Australia) | |
| Terry White Chemists Perindopril/Indapamide 4/1.25 (Australia) | |
| Tertensif Bi-Kombi (Poland) | |
| Tertensif Combi (Bulgaria) | |
| Tertensif Kombi (Denmark, Poland) | |
| Vectoryl Plus (South Africa) | |
| Vidotin Komb (Hungary) | |
| Vidotin Komb 4 mg/1.25 mg (Hungary) | |
| Voxin Combo (Slovenia) | |
See 379 substitutes for Preterax | |
References
- DailyMed. "INDAPAMIDE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubChem. "indapamide". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- PubChem. "PERINDOPRIL". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Preterax are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Preterax. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
3 consumers reported useful
Was the Preterax drug useful in terms of decreasing the symptom or the disease?According to the reports released by ndrugs.com website users, the below mentioned percentages of users say the drug is useful / not useful to them in decreasing their symptoms/disease. The usefulness of the drug depends on many factors, like severity of the disease, perception of symptom, or disease by the patient, brand name used [matters only to a certain extent], other associated conditions of the patient. If the drug is not effective or useful in your case, you need to meet the doctor to get re-evaluated about your symptoms/disease, and he will prescribe an alternative drug.
| Users | % | ||
|---|---|---|---|
| Useful | 2 | 66.7% | |
| Not useful | 1 | 33.3% | |
4 consumers reported price estimates
Was the price you paid to purchase the drug reasonable? Did you feel it was expensive?The below mentioned numbers have been reported by ndrugs.com website users about whether the Preterax drug is expensive or inexpensive. There is a mixed opinion among users. The rating about the cost of the drug depends on factors like which brand drug the patient purchased, how effective it was for the price paid, the country or place the drug is marketed, and the economic condition of the patient. The users who feel the drug is expensive can look for an alternative brand drug or a generic drug to save the cost.
| Users | % | ||
|---|---|---|---|
| Not expensive | 2 | 50.0% | |
| Expensive | 2 | 50.0% | |
5 consumers reported time for results
To what extent do I have to use Preterax before I begin to see changes in my health conditions?As part of the reports released by ndrugs.com website users, it takes > 3 month and a few days before you notice an improvement in your health conditions.
Please note, it doesn't mean you will start to notice such health improvement in the same time frame as other users. There are many factors to consider, and we implore you to visit your doctor to know how long before you can see improvements in your health while taking Preterax. To get the time effectiveness of using Preterax drug by other patients, please click here.
| Users | % | ||
|---|---|---|---|
| > 3 month | 3 | 60.0% | |
| 3 month | 1 | 20.0% | |
| 1 day | 1 | 20.0% | |
19 consumers reported age
| Users | % | ||
|---|---|---|---|
| 46-60 | 8 | 42.1% | |
| > 60 | 6 | 31.6% | |
| 30-45 | 4 | 21.1% | |
| 6-15 | 1 | 5.3% | |
Consumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
